抗真菌药在特殊人群的应用

doi:10.35541/cjd.20200035

中华皮肤科杂志 ›› 2022, Vol. 55 ›› Issue (1): 80-83.doi: 10.35541/cjd.20200035

抗真菌药在特殊人群的应用

孔雪¹ 史冬梅² 刘维达¹

¹中国医学科学院、北京协和医学院皮肤病医院真菌科，南京 210042；²山东省济宁市第一人民医院皮肤科，济宁 272001

收稿日期:2020-01-14 修回日期:2020-07-01 发布日期:2021-12-31
通讯作者: 刘维达 E-mail:liumyco@hotmail.com
基金资助:
国家十三五科技重大专项基金（2019ZX09721001）

Application of antifungal agents in special populations

Kong Xue¹, Shi Dongmei², Liu Weida¹

¹Department of Mycology, Hospital of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College, Nanjing 210042, China; ²Department of Dermatology, Jining No.1 People′s Hospital, Jining 272001, Shandong, China

Received:2020-01-14 Revised:2020-07-01 Published:2021-12-31
Contact: Liu Weida E-mail:liumyco@hotmail.com
Supported by:
National Science and Technology Major Project of China during the 13th Five-Year Plan Period（2019ZX09721001）

摘要/Abstract

摘要： 【摘要】抗真菌药物在普通人群中有较好的疗效及耐受性，但某些特殊人群，如儿童、老年人、孕妇、肝功能不全的患者，因其特殊的自身条件，抗真菌治疗面临巨大的挑战。本文综述了常见抗真菌药在以上特殊人群中的使用建议。

关键词: 抗真菌药, 儿童, 老年人, 孕妇, 肝功能不全, 无明显有害效应剂量

Abstract: 【Abstract】 Antifungal agents have shown good efficacy and tolerability in the general population. However, there are great challenges in antifungal treatments among some special populations due to their special conditions, such as children, the elderly, pregnant women and patients with hepatic insufficiency. This review summarizes recommendations for the use of common antifungal agents in the above special populations.

Key words: Antifungal agents, Child, Aged, Pregnant women, Hepatic insufficiency, No-observed-adverse-effect level

孔雪史冬梅刘维达. 抗真菌药在特殊人群的应用[J]. 中华皮肤科杂志, 2022,55(1):80-83. doi:10.35541/cjd.20200035

Kong Xue, Shi Dongmei, Liu Weida. Application of antifungal agents in special populations[J]. Chinese Journal of Dermatology, 2022, 55(1): 80-83.doi:10.35541/cjd.20200035

参考文献 41

［1］	Kaushik N, Pujalte GG, Reese ST. Superficial fungal infections［J］. Prim Care Clin Office Pract, 2015,42（4）:501⁃516. doi:10. 1016/j.pop.2015.08.004.
［2］	中国体癣和股癣诊疗指南工作组. 中国体癣和股癣诊疗指南（2018修订版）［J］. 中国真菌学杂志, 2019,14（1）:1⁃3.
［3］	Hawkins DM, Smidt AC. Superficial fungal infections in children［J］. Pediatr Clin N Am, 2014,61（2）:443⁃455. doi:10.1016/j.pcl. 2013.12.003.
［4］	Gupta AK, Mays RR, Versteeg SG, et al. Onychomycosis in children: safety and efficacy of antifungal agents［J］. Pediatr Dermatol, 2018,35（5）:552⁃559. doi: 10.1111/pde.13561.
［5］	Ameen M, Lear JT, Madan V, et al. British Association of Dermatologists′ guidelines for the management of onychomycosis 2014［J］. Br J Dermatol, 2014,171（5）:937⁃958. doi: 10.1111/bjd.13358.
［6］	Chen X, Jiang X, Yang M, et al. Systemic antifungal therapy for tinea capitis in children: an abridged Cochrane review［J］. J Am Acad Dermatol, 2017,76（2）:368⁃374. doi: 10.1016/j.jaad. 2016.08.061.
［7］	中国头癣诊疗指南工作组. 中国头癣诊断和治疗指南（2018修订版）［J］. 中国真菌学杂志, 2019,14（1）:4⁃6.
［8］	中华医学会皮肤性病学分会, 中国中西医结合学会皮肤性病专业委员会, 中国医师协会皮肤科医师分会. 中国甲真菌病诊疗指南（2015年版）［J］. 中国真菌学杂志, 2019,10（2）:118⁃125. doi: 10.3969/j.issn.1673⁃3827.2015.02.018.
［9］	Kaul S, Yadav S, Dogra S. Treatment of dermatophytosis in elderly, children, and pregnant women［J］. Indian Dermatol Online J, 2017,8（5）:310⁃318. doi: 10.4103/idoj.IDOJ_169_17.
［10］	Gupta AK, Foley KA. Antifungal treatment for pityriasis versicolor［J］. J Fungi （Basel）, 2015,1（1）:13⁃29. doi: 10.3390/jof1010013.
［11］	Ramírez SMC. Sporotrichosis: the story of an endemic region in Peru over 28 years （1985 to 2012）［J/OL］. PLoS One, 2015,10（6）:e0127924. doi: 10.1371/journal.pone.0127924.
［12］	Song Y, Li SS, Zhong SX, et al. Report of 457 sporotrichosis cases from Jilin province, northeast China, a serious endemic region［J］. J Eur Acad Dermatol Venereol, 2013,27（3）:313⁃318. doi: 10.1111/j.1468⁃3083.2011.04389.x.
［13］	中华医学会皮肤性病学分会真菌学组, 中国医师协会皮肤科医师分会医学真菌亚专业委员会, 中西医结合学会皮肤性病专业委员会真菌学组.孢子丝菌病诊疗指南［J］. 中华皮肤科杂志, 2016,49（7）:456⁃459. doi:10.3760/cma.j.issn.0412⁃4030. 2016.07.002.
［14］	Kauffman CA, Bustamante B, Chapman SW, et al. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America［J］. Clin Infect Dis, 2007,45（10）:1255⁃1265. doi: 10.1086/522765.
［15］	Groll AH, Tragiannidis A. Recent advances in antifungal prevention and treatment［J］. Semin Hematol, 2009,46（3）:212⁃229. doi: 10.1053/j.seminhematol.2009.03.003.
［16］	Hani U, Shivakumar HG, Vaghela R, et al. Candidiasis: a fungal infection⁃⁃current challenges and progress in prevention and treatment［J］. Infect Disord Drug Targets, 2015,15（1）:42⁃52. doi: 10.2174/1871526515666150320162036.
［17］	Puia⁃Dumitrescu M, Smith PB. Antifungal drugs in newborns and children［J］. Pediatr Clin North Am, 2017,64（6）:1389⁃1402. doi: 10.1016/j.pcl.2017.08.013.
［18］	Tragiannidis A, Tsoulas C, Groll AH. Invasive candidiasis and candidaemia in neonates and children: update on current guidelines［J］. Mycoses, 2015,58（1）:10⁃21. doi: 10.1111/myc. 12268.
［19］	Mantadakis E, Pana ZD, Zaoutis T. Candidemia in children: Epidemiology, prevention and management［J］. Mycoses, 2018,61（9）:614⁃622. doi: 10.1111/myc.12792.
［20］	Loo DS. Onychomycosis in the elderly : drug treatment options［J］. Drugs Aging, 2007,24（4）:293⁃302. doi: 10.2165/00002512⁃200724040⁃00003.
［21］	Gupta AK, Lane D, Paquet M. Systematic review of systemic treatments for tinea versicolor and evidence⁃based dosing regimen recommendations［J］. J Cutan Med Surg, 2014,18（2）:79⁃90. doi: 10.2310/7750.2013.13062.
［22］	Macedo PM, Lopes⁃Bezerra LM, Bernardes⁃Engemann AR, et al. New posology of potassium iodide for the treatment of cutaneous sporotrichosis: study of efficacy and safety in 102 patients［J］. J Eur Acad Dermatol Venereol, 2015,29（4）:719⁃724. doi: 10.1111/ jdv.12667.
［23］	Orofino⁃Costa R, Macedo PM, Rodrigues AM, et al. Sporotrichosis: an update on epidemiology, etiopathogenesis, laboratory and clinical therapeutics［J］. An Bras Dermatol, 2017,92（5）:606⁃620. doi: 10.1590/abd1806⁃4841.2017279.
［24］	Pappas PG, Kauffman CA, Andes DR, et al. Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America［J］. Clin Infect Dis, 2016,62（4）:409⁃417. doi: 10.1093/cid/civ1194.
［25］	Cuenca⁃Estrella M, Verweij PE, Arendrup MC, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures［J］. Clin Microbiol Infect, 2012,18 Suppl 7:9⁃18. doi: 10.1111/1469⁃0691.12038.
［26］	Brüggemann RJ, Alffenaar JW, Blijlevens NM, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents［J］. Clin Infect Dis, 2009,48（10）:1441⁃1458. doi: 10.1086/598327.
［27］	Macedo PM, Lopes⁃Bezerra LM, Bernardes⁃Engemann AR, et al. New posology of potassium iodide for the treatment of cutaneous sporotrichosis: study of efficacy and safety in 102 patients［J］. J Eur Acad Dermatol Venereol, 2015,29（4）:719⁃724. doi: 10.1111/ jdv.12667.
［28］	Stockton DL, Paller AS. Drug administration to the pregnant or lactating woman: a reference guide for dermatologists［J］. J Am Acad Dermatol, 1990,23（1）:87⁃103. doi: 10.1016/0190⁃9622（90）70192⁃k.
［29］	Patel VM, Schwartz RA, Lambert WC. Topical antiviral and antifungal medications in pregnancy: a review of safety profiles［J］. J Eur Acad Dermatol Venereol, 2017,31（9）:1440⁃1446. doi: 10.1111/jdv.14297.
［30］	Pilmis B, Jullien V, Sobel J, et al. Antifungal drugs during pregnancy: an updated review［J］. J Antimicrob Chemother, 2015,70（1）:14⁃22. doi: 10.1093/jac/dku355.
［31］	Cottreau JM, Barr VO. A review of antiviral and antifungal use and safety during pregnancy［J］. Pharmacotherapy, 2016,36（6）:668⁃678. doi: 10.1002/phar.1764.
［32］	Workowski KA. Centers for disease control and prevention sexually transmitted diseases treatment guidelines［J］. Clin Infect Dis, 2015,61 *（Suppl 8）:S759⁃S762. doi: 10.1093/cid/civ771.
［33］	Howley MM, Carter TC, Browne ML, et al. Fluconazole use and birth defects in the national birth defects prevention study［J］. Am J Obstet Gynecol, 2016,214（5）:657.e1⁃9. doi: 10.1016/j.ajog. 2015.11.022.
［34］	Barros MB, Schubach Ade O, do Valle AC, et al. Cat⁃transmitted sporotrichosis epidemic in Rio de Janeiro, Brazil: description of a series of cases. Clin Infect Dis, 2004,38（4）:529⁃535. doi: 10. 1086/381200.
［35］	Fichman V, ACFD V, de Macedo PM, et al. Cryosurgery for the treatment of cutaneous sporotrichosis in four pregnant women［J/OL］. PLoS Negl Trop Dis, 2018,12（4）:e0006434. doi: 10.1371/journal.pntd.0006434.
［36］	Mahajan VK. Sporotrichosis: an overview and therapeutic options［J］. Dermatol Res Pract, 2014,2014:272376. doi: 10.1155/2014/272376.
［37］	Carswell F, Kerr MM, Hutchison JH. Congenital goitre and hypothyroidism produced by maternal ingestion of iodides［J］. Lancet, 1970,1（7659）:1241⁃1243. doi: 10.1016/s0140⁃6736（70） 91736⁃8.
［38］	Kyriakidis I, Tragiannidis A, Munchen S, et al. Clinical hepatotoxicity associated with antifungal agents［J］. Expert Opin Drug Saf, 2017,16（2）:149⁃165. doi: 10.1080/14740338.2017. 1270264.
［39］	Khoza S, Moyo I, Ncube D. Comparative hepatotoxicity of fluconazole, ketoconazole, itraconazole, terbinafine, and griseofulvin in rats［J］. J Toxicol, 2017,2017:6746989. doi: 10.1155/2017/6746989.
［40］	Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison ［published correction appears in Drugs. 2011 Jan 22;71（2）:253］［J］. Drugs, 2011,71（1）:11⁃41. doi:10.2165/11585270⁃000000000⁃00000
［41］	Spernovasilis N, Kofteridis DP. Pre⁃existing liver disease and toxicity of antifungals［J］. J Fungi （Basel）, 2018,4（4）. doi: 10.3390/jof4040133.

[1]	李垣君寒宇阳张焕珍王慧申楠张杏莲. 度普利尤单抗治疗12例儿童慢性自发性荨麻疹回顾分析[J]. 中华皮肤科杂志, 2024, 0(4): 20230439-e20230439.
[2]	刘元香梁源赵欣荣孙玉娟马琳徐子刚. JAK抑制剂治疗儿童重症斑秃5例[J]. 中华皮肤科杂志, 2023, 56(9): 849-852.
[3]	王珊王星宇舒虹张斌石航杨欢钱秋芳马红艳梁源赵牧童申春平焦磊田晶汪洋谷盈孙婧刘盈李萍王华马琳. 克立硼罗软膏早期缓解儿童特应性皮炎临床症状及改善缓解期临床症状的多中心临床研究[J]. 中华皮肤科杂志, 2023, 56(9): 815-821.
[4]	申春平李萍罗晓燕梁源刘盈赵牧童王珊田晶焦磊汪洋罗珍余时娟方晓王华马琳. [开放获取] 某润肤霜联合周末外用糖皮质激素对延缓儿童特应性皮炎维持期疾病复发的随机、空白对照、多中心临床研究[J]. 中华皮肤科杂志, 2023, 56(8): 756-762.
[5]	袁心刚倪思利张建罗晓燕王华. 儿童黑素细胞痣的诊疗水平亟待提高[J]. 中华皮肤科杂志, 2023, 56(8): 782-786.
[6]	孙蔺波徐教生. Curry-Jones综合征1例国内首报[J]. 中华皮肤科杂志, 2023, 56(7): 626-629.
[7]	郭艳阳海璐明朱振来闫东朱冠男王刚付萌. 头癣致病病原菌单中心回顾性分析[J]. 中华皮肤科杂志, 2023, 56(6): 531-533.
[8]	周亚彬肖媛媛晁金京马琳. 口服特比萘芬与伊曲康唑治疗儿童头癣的疗效比较[J]. 中华皮肤科杂志, 2023, 56(5): 438-440.
[9]	任发亮王华肖异珠. 透明细胞丘疹病57例临床特征分析[J]. 中华皮肤科杂志, 2023, 56(4): 309-312.
[10]	孙培文王乐王洪生严良斌余美文. 2016—2020年中国麻风病流行病学特征分析[J]. 中华皮肤科杂志, 2023, 56(3): 204-209.
[11]	田晶梁源马琳. 度普利尤单抗治疗儿童特应性皮炎的研究进展[J]. 中华皮肤科杂志, 2023, 0(2): 20210730-e20210730.
[12]	王召阳向欣陈云刘苗朝阳赵欣荣张振华刘元香马琳徐子刚. 生物制剂与甲氨蝶呤治疗儿童重度斑块状银屑病疗效及安全性比较[J]. 中华皮肤科杂志, 2023, 56(2): 112-117.
[13]	贾元源毛秋雨杨婧怡闵玮. 度普利尤单抗治疗中重度老年特应性皮炎临床疗效观察[J]. 中华皮肤科杂志, 2023, 56(2): 125-129.
[14]	中华医学会皮肤性病学分会中国康复医学会皮肤病康复专业委员会中国中西医结合学会皮肤性病学分会中国医药教育协会皮肤病专业委员会. 老年带状疱疹诊疗专家共识[J]. 中华皮肤科杂志, 2023, 56(2): 97-104.
[15]	邓维张高磊陈见友张升蒋丽潇刘晓雁苏伟. 61例儿童新型冠状病毒感染的皮肤表现分析[J]. 中华皮肤科杂志, 2023, 56(12): 1154-1157.

抗真菌药在特殊人群的应用

Application of antifungal agents in special populations

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 41

相关文章 15

Metrics

本文评价

推荐阅读 10